This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZFGN Zafgen (ZFGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Zafgen Stock (NASDAQ:ZFGN) Get Zafgen alerts:Sign Up Key Stats Today's Range$5.05▼$5.3550-Day Range$0.99▼$25.0652-Week Range$0.62▼$2.76Volume1.32 million shsAverage Volume360,199 shsMarket Capitalization$190.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Read More Receive ZFGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZFGN Stock News HeadlinesTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030April 9, 2023 | marketwatch.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 15 at 1:00 AM | Chaikin Analytics (Ad)Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug ResultsFebruary 26, 2023 | thestreet.comZafgen (ZFGN) Stock Surges on Positive Obesity Drug TrialJanuary 13, 2023 | thestreet.comFood and drink in a castleNovember 8, 2022 | bbc.co.ukLRMR Larimar Therapeutics, Inc.September 30, 2022 | seekingalpha.comForm 424B5 Larimar Therapeutics, - StreetInsider.comSeptember 14, 2022 | streetinsider.comSee More Headlines ZFGN Stock Analysis - Frequently Asked Questions How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) released its earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zafgen investors own include Bristol Myers Squibb (BMY), Energy Transfer (ET), BlackRock (BLK), TG Therapeutics (TGTX) and SCYNEXIS (SCYX). Company Calendar Last Earnings3/05/2020Today8/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZFGN CIK1374690 Webwww.zafgen.com Phone617-622-4003FaxN/AEmployees38Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-34.55% Debt Debt-to-Equity Ratio0.26 Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book3.77Miscellaneous Outstanding Shares37,470,000Free FloatN/AMarket Cap$190.72 million OptionableNot Optionable Beta0.27 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ZFGN) was last updated on 8/15/2026 by MarketBeat.com Staff. From Our PartnersReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.